Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6302MR)

This product GTTS-WQ6302MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Solid tumors, research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6302MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14803MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-70
GTTS-WQ13370MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PR-1498487
GTTS-WQ1104MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ7612MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ6499MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CX-072
GTTS-WQ7417MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GA201
GTTS-WQ9787MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JS002
GTTS-WQ1040MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-399
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW